Clinical trial
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
NCT05386108 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
- Lead sponsor
- Stemline Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 31, 2022
- Completion date
- December 31, 2026
- Enrollment
- 73 (estimated)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.